Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None2021202020192018201720162015 Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting 12/11/2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting 12/05/2017 Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit 11/14/2017 Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 11/08/2017 Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma 10/26/2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat 10/05/2017 Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma 09/26/2017 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit 09/06/2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting 06/05/2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Next page next › Last page last » Displaying 41 - 50 of 61
Year None2021202020192018201720162015 Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting 12/11/2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting 12/05/2017 Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit 11/14/2017 Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 11/08/2017 Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma 10/26/2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat 10/05/2017 Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma 09/26/2017 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit 09/06/2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting 06/05/2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Next page next › Last page last » Displaying 41 - 50 of 61
Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting 12/11/2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting 12/05/2017
Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit 11/14/2017
Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 11/08/2017
Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma 10/26/2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat 10/05/2017
Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma 09/26/2017
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting 06/05/2017
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017